Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling

作者: Fabio Conforti , Yisong Wang , Jose A. Rodriguez , Anna Teresa Alberobello , Yu-Wen Zhang

DOI: 10.1158/1078-0432.CCR-15-0408

关键词: CytoplasmMAPK/ERK pathwayXPO1PathogenesisNuclear transportCancer cellTumor progressionBiologyCell biologyNuclear export signal

摘要: A dynamic distribution between nucleus and cytoplasm (nucleocytoplasmic shuttling) is one of the control mechanisms adapted by normal cells to regulate activity a variety molecules. Growing evidence suggests that dysregulation nucleocytoplasmic shuttling involved in promoting abnormal cell survival, tumor progression, drug resistance, associated with poor cancer prognosis. Aberrant may result from hyperactive status diverse signal-transduction pathways, such as PI3K-AKT MAPK or alterations general nuclear import/export machinery. Among large number molecules process, exportin XPO1, also known chromosome region maintenance 1, appears play particularly prominent role pathogenesis both hematological malignancies solid tumors. Given importance rapidly expanding knowledge this field, attempts have been made develop compounds able revert aberrant shuttling. promising new drug, KPT-330 (Selinexor), which belongs class XPO1 inhibitors called selective export, now being tested phase I/II clinical trials.

参考文章(62)
Anatoly Y. Nikolaev, Muyang Li, Norbert Puskas, Jun Qin, Wei Gu, Parc: A Cytoplasmic Anchor for p53 Cell. ,vol. 112, pp. 29- 40 ,(2003) , 10.1016/S0092-8674(02)01255-2
Douglass J Forbes, Anna Travesa, Matthew S Nord, Cyril Bernis, Nuclear transport factors: global regulation of mitosis. Current Opinion in Cell Biology. ,vol. 35, pp. 78- 90 ,(2015) , 10.1016/J.CEB.2015.04.012
Janet Mendonca, Anup Sharma, Hae-Soo Kim, Hans Hammers, Alan Meeker, Angelo De Marzo, Michael Carducci, Michael Kauffman, Sharon Shacham, Sushant Kachhap, Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer Oncotarget. ,vol. 5, pp. 6102- 6112 ,(2014) , 10.18632/ONCOTARGET.2174
U M Moll, A G Ostermeyer, R Haladay, B Winkfield, M Frazier, G Zambetti, Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Molecular and Cellular Biology. ,vol. 16, pp. 1126- 1137 ,(1996) , 10.1128/MCB.16.3.1126
C. Hilmi, L. Larribere, M. Deckert, S. Rocchi, S. Giuliano, K. Bille, J.P. Ortonne, R. Ballotti, C. Bertolotto, Involvement of FKHRL1 in melanoma cell survival and death. Pigment Cell & Melanoma Research. ,vol. 21, pp. 139- 146 ,(2008) , 10.1111/J.1755-148X.2008.00440.X
Mickey C.-T Hu, Dung-Fang Lee, Weiya Xia, Leonard S Golfman, Fu Ou-Yang, Jer-Yen Yang, Yiyu Zou, Shilai Bao, Norihisa Hanada, Hitomi Saso, Ryuji Kobayashi, Mien-Chie Hung, IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a Cell. ,vol. 117, pp. 225- 237 ,(2004) , 10.1016/S0092-8674(04)00302-2
Jennifer Yang, Matthew A. Bill, Gregory S. Young, Krista La Perle, Yosef Landesman, Sharon Shacham, Michael Kauffman, William Senapedis, Trinayan Kashyap, Jean-Richard Saint-Martin, Kari Kendra, Gregory B. Lesinski, Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells PLoS ONE. ,vol. 9, pp. e102983- ,(2014) , 10.1371/JOURNAL.PONE.0102983
Elizabeth J. Tran, Megan C. King, Anita H. Corbett, Macromolecular transport between the nucleus and the cytoplasm: Advances in mechanism and emerging links to disease. Biochimica et Biophysica Acta. ,vol. 1843, pp. 2784- 2795 ,(2014) , 10.1016/J.BBAMCR.2014.08.003
Wenge Lu, Radhika Pochampally, Lihong Chen, Mullika Traidej, Yiliang Wang, Jiandong Chen, Nuclear exclusion of p53 in a subset of tumors requires MDM2 function Oncogene. ,vol. 19, pp. 232- 240 ,(2000) , 10.1038/SJ.ONC.1203262